Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health Science to Targeted Risk Assessment

The legacy context of general health and science information has long provided a foundation for understanding broad wellness principles and the mechanisms of disease prevention. Within this framework, public databases such as ClinicalTrials.gov and PubMed have served as authoritative sources for structured data on therapeutic interventions and their outcomes. This heritage emphasizes the importance of evidence-based knowledge, where clinical trial registries and peer-reviewed literature inform both medical professionals and the public about treatment efficacy and safety profiles. Transitioning from this general health perspective, a more focused examination of occupational and environmental exposures becomes pertinent. Specifically, the relationship between pharmaceutical agents and long-term health risks warrants careful scrutiny. In the domain of mass production, where workers may encounter chemical or biological agents, understanding the potential consequences of exposure is critical. This pivot directs attention toward the specific case of Avelumab, a therapeutic monoclonal antibody, and its association with Merkel Cell Carcinoma risk. While the legacy context provides the tools for data analysis, the occupational exposure concern reframes the inquiry: what do clinical studies and post-marketing surveillance reveal about the risk of developing Merkel Cell Carcinoma following Avelumab administration? This shift moves from general health literacy to a targeted risk assessment relevant to occupational health and safety.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Evidence on Avelumab and MCC Risk: Causation vs. Treatment

Regarding causation-related considerations, avelumab is used as a treatment for MCC, not as a cause of the disease. The evidence indicates that avelumab is an approved therapy for metastatic MCC, and its use is associated with clinical benefit in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). The risk of developing MCC is not linked to avelumab exposure; rather, avelumab is administered to patients who already have MCC. The timeline between exposure and documented harm is relevant to adverse events from avelumab therapy, which can occur during treatment. Immune-related adverse events are a known risk of immune checkpoint inhibitors, including avelumab, and can arise at various points during the treatment course (https://pubmed.ncbi.nlm.nih.gov/34445385/). The adequacy of warnings regarding avelumab and MCC is addressed through the drug's prescribing information, which includes information on its approved indication for metastatic MCC and potential adverse effects. The evidence does not suggest that avelumab causes MCC; instead, it is a therapeutic agent for the disease.

Management of Avelumab-Refractory Merkel Cell Carcinoma

In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of patients with metastatic MCC who were refractory to avelumab and later treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Three out of five patients investigated responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further supports the use of this combination in patients who have progressed on avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, avelumab is an established treatment for metastatic MCC, with evidence from clinical trials showing efficacy in a subset of patients. The risk of MCC is not attributable to avelumab exposure, and the drug's role is therapeutic rather than causative. Patients who do not respond to avelumab or who experience progression may be considered for alternative therapies, such as combined ipilimumab and nivolumab, based on retrospective studies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC. The risk of developing MCC is linked to UV exposure and Merkel cell polyomavirus, not avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What is the evidence for avelumab in Merkel cell carcinoma?

Avelumab was approved based on the JAVELIN Merkel 200 trial, showing objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Response rates to PD-1/PD-L1 inhibitors can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).

What are the treatment options for patients who progress on avelumab?

For patients refractory to avelumab, combined ipilimumab and nivolumab has shown efficacy in retrospective studies, with responses observed in some patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.